The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma

Journal of Experimental & Clinical Cancer Research

Yang Gao²  Dianrong Xiu¹  Weiqiang Ran³  Suqing Tian²  Jinna Li²  Yuliang Jiang²  Junjie Wang²  Hao Wang² 

[1] Department of Surgery, Peking University 3rd Hospital, Beijing 100083, P. R. China;Department of Radiation Oncology, Peking University 3rd Hospital, Huan-yuan North Road 49th, Beijing 100083, P. R. China;Department of Ultrasound, Peking University 3rd Hospital, Beijing 100083, P. R. China

关键词: Pancreatic carcinoma;    Unresectable;    Ultrasound-guided;    Intraoperative implantation;    ¹²⁵I seed;   

Others  :  813930
DOI  :  10.1186/1756-9966-32-106

 received in 2013-06-13, accepted in 2013-12-24,  发布年份 2013

【 摘 要 】

Background

To assess the efficacy of intraoperative ultrasound-guided implantation of ¹²⁵I seeds for the treatment of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.

Methods

Twenty-eight patients with pancreatic carcinoma who underwent laparotomy and were considered to have unresectable tumors were included in this study. Nine patients were pathologically diagnosed with Stage II disease, and nineteen patients with Stage III disease. Twenty-eight patients received intraoperative ultrasound-guided ¹²⁵I seed implantation and received a D₉₀ (at least 90% of the tumor volume received the reference dose) ranging from 60 to 163 Gy, with a median of 120 Gy. Seven patients received an additional 35–50 Gy external beam radiotherapy after seed implantation, and ten patients received two to ten cycles of chemotherapy. Overall survival of the patients was calculated and prognostic factors were evaluated.

Results

Of the patients, 94.1% (16/17) achieved good to medium pain relief. The tumor response rate was 78.6% (22/28), and local control was achieved in 85.7% (24/28) of patients. The 1-, 2- and 3-year survival rates were 30%, 11% and 4%, and the median survival was 10.1 months (95% CI: 9.0-10.9). Analysis using the Cox proportional hazards model suggested that patients younger than 60 years and patients who received a D₉₀ higher than 110 Gy may survive for a longer period.

Conclusions

I seed implantation provides a safe and effective method to relieve pain, control local tumor growth and, to some extent, prolong the survival of patients with stage II and III pancreatic disease, without additional complications. Age and accumulated dose may be factors predictive of a favorable outcome for patients with unresectable pancreatic carcinoma treated with ¹²⁵I seeds. These findings need to be validated by conducting further studies with larger cohorts.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [2]Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995, 221:721-731.
• [3]Wang C, Wu H, Xiong J, Zhou F, Tao J, Liu T, Zhao G, Gou S: Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study. J Gastrointest Surg 2008, 12:2183-2190.
• [4]National Comprehensive Cancer Network: Practice guidelines in oncology: pancreatic carcinoma 2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf webcite
• [5]Furuse J, Ogino T, Ryu M, Kinoshita T, Konishi M, Kawano N, Ishikura S, Shimizu W, Sekiguchi R, Moriyama N, Iwasaki M, Yoshino M: Intraoperative and conformal external-beam radiation therapy in patients with locally advanced pancreatic carcinoma, results from a feasibility phase II study. Hepatogastroenterology 2000, 47:1142-1146.
• [6]Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, Nakagohri T, Inoue K, Ogino T, Ikeda H, Maru Y, Yoshino M: Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer 2003, 97:1346-1352.
• [7]Wang JJ, Jiang YL, Li JN, Tian SQ, Ran WQ, Xiu D: Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J Exp Clin Cancer Res 2009, 28:1-6. BioMed Central Full Text
• [8]Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47:207-214.
• [9]International Association for the Study of Pain, Subcommittee on Taxonomy: Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain 1986, 3(Suppl):221-226.
• [10]Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813.
• [11]Gillen S, Schuster T, Friess H, Kleeff J: Palliative resections versus palliative bypass procedures in pancreatic cancer–a systematic review. Am J Surg 2012, 203:496-502.
• [12]Gutt R, Liauw SL, Weichselbaum RR: The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol 2010, 7:437-447.
• [13]Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751-755.
• [14]Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset J, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-1599.
• [15]Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract]. J Clin Oncol 2008, 26:a4506.
• [16]Ioka T, Nakamura S, Nishiyama K: A randomized phase II study of gemcitabine 1000 mg/msq and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma [abstract]. Int J Radiat Oncol Biol Phys 2010, 78:S102.
• [17]Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Berthelsen A, Eberholst F, Engelholm SA, von der Maase H: Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005, 76:48-53.
• [18]Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C: Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010, 78:735-742.
• [19]Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC: Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011, 81:181-188.
• [20]Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G: Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010, 17:2092-2101.
• [21]Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A: Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. Pancreatology 2011, 11:68-75.
• [22]Ogawa K, Karasawa K, Ito Y, Ogawa Y, Jingu K, Onishi H, Aoki S, Wada H, Kokubo M, Ogo E, Etoh H, Kazumoto T, Takayama M, Nemoto K, Nishimura Y: Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys 2011, 80:111-118.
• [23]Pfreundner L, Baier K, Schwab F, Willner J, Bratengeier K, Flentje M, Feustel H, Fuchs KH: 3D-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome. Strahlenther Onkol 1998, 174:133-141.
• [24]Wang J, Wang J, Liao A, Zhuang H, Zhao Y: The direct biologic effects of radioactive 125I seeds on pancreatic cancer cells PANC-1, at continuous low-dose rates. Cancer Biother Radiopharm 2009, 24:409-416.
• [25]Ma J, Jin Z, Si P, Liu Y, Lu Z, Wu H, Pan X, Wang L, Gong Y, Gao J, Li Z: Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth. J Exp Clin Cancer Res 2011, 30:35-46. BioMed Central Full Text
• [26]Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, Jin J, Wang K, Xiao H, Li S, Li Z: Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res 2013, 32:86-95. BioMed Central Full Text
• [27]Ma Z, Yang Y, Zou L, Luo K: 125I seed irradiation induces up-regulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts. J Exp Clin Cancer Res 2012, 31:61-70. BioMed Central Full Text
• [28]Zhuang H, Wang J, Liao A, Wang J, Zhao Y: The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res 2009, 28:12-10. BioMed Central Full Text
• [29]Shipley WU, Nardi GL, Cohen AM, Ling CC: Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection. Cancer 1980, 45:709-714.
• [30]Handley WS: Pancreatic cancer and its treatment by implanted radium. Ann Surg 1934, 100:215-223.
• [31]Hilaris BS, Roussis K: Cancer of the Pancreas. In Handbook of Radiotherapy Brachytherapy. Edited by Hilaris BS. American National Cancer Institute, Acton Mass Publishing Sciences Group; 1975:251-262.
• [32]Morrow M, Hilaris B, Brennan MF: Comparison of conventional surgical resection, radioactive implantation, and bypass procedures for exocrine carcinoma of the pancreas 1975–1980. Ann Surg 1984, 199:1-5.
• [33]Syed AM, Puthawala AA, Neblett DL: Interstitial iodine-125 implant in the management of unresectable pancreatic carcinoma. Cancer 1983, 52:808-813.
• [34]Peretz T, Nori D, Hilaris B, Manolatos S, Linares L, Harrison L, Anderson LL, Fuks Z, Brennan MF: Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 1989, 17:931-935.
• [35]Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997, 79:1516-1520.
• [36]Andre T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, Colonna M, Lotz JP, De Gramont A, Bellaïche A, Parc R, Touboul E, Izrael V: Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: Results of a feasibility study. Int J Radiat Oncol Biol Phys 2000, 46:903-911.
• [37]Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, Haider K, Kwasny W, Locker G, Scheithauer W: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 2000, 82:98-103.
• [38]Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, Talamini R, Trovò MG: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2001, 51:736-740.